Please use this identifier to cite or link to this item:
Title: Early waning of maternal measles antibodies in era of measles elimination: longitudinal study
Authors: Leuridan, E.
HENS, Niel 
Hutse, V.
Leven, M.
AERTS, Marc 
Van Damme, P.
Issue Date: 2010
Abstract: Objective To investigate the duration of the presence of maternal antibodies to measles in infants. Design Prospective study (May 2006 to November 2008). Setting Five hospitals in the Province of Antwerp, Belgium. Participants Of 221 pregnant women recruited, 207 healthy woman-infant pairs were included-divided into a vaccinated group (n=87) and naturally immune group (n=120), according to vaccination documents and history. Main outcome measure Measles IgG antibodies measured by enzyme linked immunosorbent assay (ELISA) at seven time points (week 36 of pregnancy, birth (cord), and 1, 6, 9, and 12 months); decay of maternal antibody in infants modelled with linear mixed models. Results Vaccinated women had significantly fewer IgG antibodies (geometric mean titre 779 (95% confidence interval 581 to 1045) mIU/ml) than did naturally immune women (2687 (2126 to 3373) mIU/ml) (P<0.001). Maternal values were highly correlated with neonatal values (r=0.93 at birth). Infants of vaccinated women had significantly lower antibody concentrations than did infants of naturally immune women (P<0.001 at all ages over the follow-up period). Presence of maternal antibodies endured for a median of 2.61 months-3. 78 months for infants of naturally infected women and 0. 97 months for infants of vaccinated women. At 6 months of age, more than 99% of infants of vaccinated women and 95% of infants of naturally immune women had lost maternal antibodies according to the model. Conclusions This study describes a very early susceptibility to measles in infants of both vaccinated women and women with naturally acquired immunity. This finding is important in view of recent outbreaks and is an argument for timeliness of the first dose of a measles vaccine and vaccination of travelling or migrating children under the age of 1 year.
Notes: [Leuridan, E.; Van Damme, P.] Univ Antwerp, Fac Med, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, B-2610 Antwerp, Belgium. [Hens, N.; Aerts, M.] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BIOST, Hasselt, Belgium. [Hens, N.] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Hlth Econ Res & Modelling Infect Dis, B-2610 Antwerp, Belgium. [Hutse, V.] Sci Inst Publ Hlth, Programme Virol, Natl Lab Measles & Rubella, Brussels, Belgium. [Leven, M.] Univ Antwerp, Fac Med, Dept Med Microbiol, Vaccine & Infect Dis Inst, B-2610 Antwerp, Belgium.
Document URI:
ISSN: 0959-535X
DOI: 10.1136/bmj.c1626
ISI #: 000278061500001
Category: A1
Type: Journal Contribution
Validations: ecoom 2011
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Leuridan_et_al._BMJ_(authors_version)[1].pdfarticle337.91 kBAdobe PDFView/Open
Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.